[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341991-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341991-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","investigation-of-association-between-clinically-significant-prostate-cancer-obesity-and-platelet-to-lymphocyte-ratio-and-neutrophil-to-lymphocyte-ratio","Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil-to-lymphocyte ratio","","Blood markers linked to inflammation are known to be elevated in prostate cancer and may carry prognostic value, yet their relationships with clinically significant disease and other chronic inflammation drivers remain unclear. This study analyzes how neutrophil- and platelet-derived indices adjusted to lymphocyte counts (NLR and PLR) relate to clinically significant prostate cancer while accounting for systemic inflammation and key confounders. A multicenter prospective cohort evaluates these markers using comparative tests, multivariable logistic regression, and exploratory ROC cutoffs.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/investigation-of-association-between-clinically-significant-prostate-cancer-obesity-and-platelet-to-lymphocyte-ratio-and-neutrophil-to-lymphocyte-ratio/341991/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/investigation-of-association-between-clinically-significant-prostate-cancer-obesity-and-platelet-to-lymphocyte-ratio-and-neutrophil-to-lymphocyte-ratio/341991.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What inflammation-related blood markers were studied in relation to clinically significant prostate cancer?","Question",{"text":63,"@type":64},"The study evaluated NLR (neutrophil-to-lymphocyte ratio) and PLR (platelet-to-lymphocyte ratio), along with platelet-related measures such as plateletcrit and platelet count.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was clinically significant prostate cancer defined?",{"text":68,"@type":64},"Clinically significant prostate cancer was defined using a Gleason score threshold of at least 4 + 3.",{"name":70,"@type":61,"acceptedAnswer":71},"Did the study find an association between these inflammation markers and clinically significant disease?",{"text":72,"@type":64},"After adjustment, there was no association between PLR, NLR, plateletcrit, platelet count, and clinically significant prostate cancer, and exploratory analyses also found no clinically meaningful predictive cutoff in ROC testing.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341991,1790211847,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":106,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Dahan etal. BMC Urology (2024) 24:226 [https://doi.org/10.1186/s12894-024-01617-2](https://doi.org/10.1186/s12894-024-01617-2)  \nBMC Urology  \nRESEARCH Open Access  \nInvestigation of association between  \nclinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil-to-lymphocyte ratio  \nJohanna Dahan 1, Jehonathan Pinthus2,3, Guila Delouya 1, Daniel Taussky 1*, Emmanuelle Duceppe4, Amanda de Jesus5 and Darryl Leong6  \nAbstract  \nIntroduction Several blood markers of inflammation are elevated in prostate cancer (PCa) and have prognostic value. Little is known about the relationship between these markers, PCa, and other factors associated with chronic inflammation, such as smoking and obesity. We analyzed the interaction between neutrophil and platelet counts indexed to lymphocyte count (NLR and PLR, resp.) and clinically significant PCa (csPCa), accounting for the potential confounding factors of systemic inflammation.  \nMethods NLR and PLR were evaluated in a multicenter prospective study in 443 patients. CsPCa was defined asa Gleason ≥ 4 + 3. Differences between patients with csPCa and non-csPCA were evaluated using the chi-square test, analysis of variance or the Kruskal-Wallis test. Multivariable logistic regression analysis adjusted for smoking, hypertension, diabetes, and cardiovascular disease, and in separate models, either body mass index or waist-to-hip ratio was used to characterize the relationship between inflammation and csPCa.  \nResults None of the factors such as plateletcrit, NLR, and PLR were significantly different between patients with csPCa or non-significant PCa. After adjustment, there was no association between PLR, NLR, plateletcrit or platelet count and csPCa. In an exploratory analysis, there was no association between markers of inflammation and PSA levels > 10 ng/mL. When testing different NLR cutoffs to predict csPCa in ROC analysis, none reached a clinically meaningful value.  \nConclusion In contrast to previous studies, we found no significant association between easily available blood markers of inflammation and indices of PCa aggressiveness. Further research is required to determine whether inflammation promotes PCa. ([ClinicalTrials.gov:](ClinicalTrials.gov:) NCT03127631 . Date of registration: April 25, 2017.  \nKeywords Prostate cancer, Obesity, Inflammation, NLR  \n*Correspondence:  \nDaniel Taussky [daniel.taussky.chum@ssss.gouv.qc.ca](daniel.taussky.chum@ssss.gouv.qc.ca)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nDahan et al. BMC Urology (2024) 24:226  \nIntroduction  \nThe association between obesity and prostate cancer (PCa) is complex, because obesity is associated at the same time with more aggressive cancer, while at the sametime obesity is associated with a decrease in less aggressive cancer [1, 2]. Obesity causes chronic low-grade inflammation which in turn is associated with PCa [3, 4]. Inflammation can change the tumor-microenvironment in PCa and attract different immune-cells and therefore modify the immune-response [5]. Cytokin","cbCaidmoShO6X0DN","https://ap.wps.com/l/cbCaidmoShO6X0DN","pdf",1378435,"English","# Abstract\n## Introduction\n## Materials and methods\n### The study, endpoints and exclusion criteria\n## Results\n## Conclusion","[{\"question\":\"What inflammation-related blood markers were studied in relation to clinically significant prostate cancer?\",\"answer\":\"The study evaluated NLR (neutrophil-to-lymphocyte ratio) and PLR (platelet-to-lymphocyte ratio), along with platelet-related measures such as plateletcrit and platelet count.\"},{\"question\":\"How was clinically significant prostate cancer defined?\",\"answer\":\"Clinically significant prostate cancer was defined using a Gleason score threshold of at least 4 + 3.\"},{\"question\":\"Did the study find an association between these inflammation markers and clinically significant disease?\",\"answer\":\"After adjustment, there was no association between PLR, NLR, plateletcrit, platelet count, and clinically significant prostate cancer, and exploratory analyses also found no clinically meaningful predictive cutoff in ROC testing.\"}]","Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil-to-lymphocyte ratio | PDF",1790044661,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/809b55fefc5fad9176f7960ad55f661c.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6446ab23042b6c1901b82d4e12b095a0.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f574a562e4c55551a98e6db973e547e8.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a83c21eefe87e801a6453158f5109806.webp",980,1306]